Xilio Therapeutics
Localized immunotherapy delivery system for intratumoral cancer treatment
- Sector
- Biotech
- Headquarters
- WALTHAM, MA
- Founded
- 2020
- Latest Form D
- $95M, Feb 2021
- Total capital
- $145M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $145M
- 2 Form D · last Feb 2021
- 68 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 3 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$95M
- Private capital raisedForm D · SEC · 1st filing$50.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Andrew HackDirectorNamed in SEC Form D filings
- Daniel CurranDirectorNamed in SEC Form D filings
- Daniel LynchDirectorNamed in SEC Form D filings
- David GardnerDirectorNamed in SEC Form D filings
- David GrayzelDirectorNamed in SEC Form D filings
- Joseph FarmerExecutive OfficerNamed in SEC Form D filings
Show all 14 people
- Michael RossDirectorNamed in SEC Form D filings
- Nancy HongDirectorNamed in SEC Form D filings
- Paul ClancyDirectorNamed in SEC Form D filings
- Peter DudekDirectorNamed in SEC Form D filings
- Rachel HumphreyDirectorNamed in SEC Form D filings
- Rene RussoExecutive Officer, DirectorNamed in SEC Form D filings
- Robert WeisskoffDirectorNamed in SEC Form D filings
- Timothy ClacksonExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 3- PendingMasked Cytokine PolypeptidesUSPTOApplication 62891199
- PendingMasked Cytokine PolypeptidesUSPTOApplication 62888276
- PendingMasked Cytokine PolypeptidesUSPTOApplication 62737803
Related companies, and why
- Hexagon Bio Inc.Similar federal contract value in Biotech · null in contracts
- Dovetail Genomics, LLCSimilar federal contract value in Biotech · null in contracts
- SimBioSys, Inc.Similar federal contract value in Biotech · null in contracts
- EvozyneSimilar federal contract value in Biotech · null in contracts
- ASTROCYTE PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
- Ajax TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .